Azitra, Inc.

Focused on Execution and Long-Term Value Creation

We continue to execute on our vision by advancing our clinical pipeline, strengthening our scientific and intellectual property foundation, and expanding the potential applications of our proprietary technologies into broader commercial opportunities.

We are building a differentiated biotechnology platform at the intersection of precision dermatology, synthetic biology, and artificial intelligence, while pursuing multiple opportunities that we believe can create meaningful long-term value for customers, patients and shareholders alike. Financial discipline and operational execution remain central to our strategy, and we remain focused on efficiently deploying capital toward programs and initiatives that we believe have the greatest potential to generate meaningful clinical progress and shareholder value.

Looking ahead, we anticipate multiple important catalysts across our pipeline, including continued clinical advancement, additional scientific presentations and further expansion of our platform technologies. We believe the progress we have achieved reflects the dedication of our team, the strength of our science and the growing recognition of Azitra’s differentiated approach to precision dermatology and genetic engineering.